Merieux/Connaught rabies vaccine
Federal Trade Commission releases Pasteur-Merieux from obligation to sell Connaught's rabies vaccine to a third party in an April 29 order, citing the company's inability to find an acceptable buyer and public health considerations. Merieux filed a motion with the FTC in December to be released from a consent order mandating the sale of the Connaught rabies vaccine ("The Pink Sheet" Jan. 17, T&G-10)
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth